A Phase 2 interventional study of Fluticasone propionate 100mcg and Placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 121 sites in 14 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-01-09.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing vilanterol in Asthma — none open to participants now, 2 under way, 2 of them phase 3. vilanterol · Asthma.
Among the 30 studies testing vilanterol in Asthma, this one is the 4th largest by enrollment, is one of 5 that started in 2012, is one of 6 in phase 2, and was the 18th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 30 studies testing vilanterol in Asthma is open now. The open studies under Asthma, anywhere →
vilanterol: first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 5 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 463 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 69 across the 30 interventional studies. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 30 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 48th largest by enrollment of the 238 interventional ones that give a count, is one of 23 that started in 2012, is one of 59 in phase 2, and was the 144th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing vilanterol in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing vilanterol in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a Phase IIb, multi-centre, randomised, double-blind, parallel-group, placebo-controlled study in children aged 5-11 years with persistent uncontrolled asthma. Subjects entering the run-in period will stop their current asthma medication and be given open label fluticasone propionate (FP) 100mcg twice daily via DISKUS/ACCUHALER and salbutamol/albuterol as required to use throughout the run-in and double-blind treatment period. At Visit 3 subjects meeting the randomization eligibility criteria will receive vilanterol (6.25mcg, 12.5mcg, or 25mcg,) or placebo via the Novel Dry Powder Inhaler (NDPI) once daily for 4 weeks in addition to open-label fluticasone propionate twice daily throughout the treatment period. Primary endpoints consist of change from baseline in clinic visit trough (pre-bronchodilator and pre-dose) PEF at the end of the 28-day treatment period in all subjects. Safety assessments include adverse events, oropharyngeal examinations, clinical chemistry, 12-lead ECG, and vital signs. Blood samples will be taken from all subjects for pharmacokinetic analysis to determine plasma concentrations of vilanterol at specific time intervals relative to the dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vilanterol 25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
Drug: Fluticasone propionate 100mcg · Drug: Vilanterol
Vilanterol 12.5mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
Drug: Fluticasone propionate 100mcg · Drug: Vilanterol
Vilanterol 6.25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
Drug: Fluticasone propionate 100mcg · Drug: Vilanterol
Placebo inhalation powder inhaled once daily in the PM via the new powder inhaler
Drug: Fluticasone propionate 100mcg · Drug: Placebo
all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
Placebo inhalation powder during treatment period
subjects will recieve 4 weeks via NDPI during treament period
Change From Baseline in Daily Pre-dose Evening (PM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 4-week Treatment Period
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use each morning. The best of three measurements was recorded. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 4-week Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Phase. The analysis was performed using an analysis of covariance (ANCOVA) model with covariates of Baseline, region, sex, age, and treatment. Only those participants contributing data per the daily eDiary were analyzed.
Time frame: Baseline; Week 1 up to Week 4
Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 4-week Treatment Period in Children Who Could Perform the Maneuver
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as a pre-dose FEV1 measurement taken at a clinic visit while still on treatment. Change from Baseline in trough FEV1 at the end of the 4-week Treatment Period was defined using the pre-dose FEV1 measurement taken at the Week 4 clinic visit. Change from Baseline was calculated as the Week 4 trough FEV1 value minus the Baseline value. The Baseline FEV1 value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline trough FEV1, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.
Time frame: Baseline; Week 4
Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 4-week Treatment Period
The number of inhalations of rescue albuterol/salbutamol inhalation aerosol (medication used to relieve symptoms immediately) used during the day and night) was recorded by the participants in a daily diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Participants who were rescue free for 24-hour periods during the 4-week Treatment Period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline is calculated as the average value during the 4-week Treatment Period minus the value at Baseline. The Baseline value is defined as the value at Visit 3 (randomization). Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
Time frame: Baseline; Week 1 up to Week 4
Change From Baseline in Daily Morning (AM) PEF Averaged Over the 4-week Treatment Period
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 4-week Treatment Period (at Week 4) minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
Time frame: Baseline; Week 1 up to Week 4
Change From Baseline in Evening (PM) PEF Over the Last 7 Days of the Treatment Period (Week 4)
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline is calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.
Time frame: Baseline; Week 4
Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 4)
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline is calculated as the value of the averaged daily AM PEF over the 4-week Treatment Period (at Week 4) minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
Time frame: Baseline; Week 4
Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 4-week Treatment Period
Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the PEF measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline symptom-free value is defined as the value at Visit 3 (randomization). Change from Baseline was calculated as the averaged value during the 4-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
Time frame: Baseline; Week 1 up to Week 4
1208 participants (par.) were screened; 760 entered the Run-in Phase, 463 were randomized, and 2 received study medication (SM) but weren't randomized/included in the Intent-to-Treat (ITT) Population (randomized to treatment and receiving \>=1 SM dose). 7 randomized par. didn't receive SM; hence, 456 par. comprised the ITT Population.
| Milestone | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Started | 115 | 114 | 113 | 114 |
| Completed | 93 | 93 | 99 | 90 |
| Not completed | 22 | 21 | 14 | 24 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 18 | 15 | 12 | 17 |
| Withdrew: Protocol violation | 3 | 1 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 1 |
| Withdrew: Physician decision | 1 | 2 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use each morning. The best of three measurements was recorded. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 4-week Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Phase. The analysis was performed using an analysis of covariance (ANCOVA) model with covariates of Baseline, region, sex, age, and treatment. Only those participants contributing data per the daily eDiary were analyzed.
| Liters per minute (L/min) | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Change From Baseline in Daily Pre-dose Evening (PM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 4-week Treatment Period | 215.9 ± 2.53 | 221.4 ± 2.53 | 222.4 ± 2.54 | 220.3 ± 2.56 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as a pre-dose FEV1 measurement taken at a clinic visit while still on treatment. Change from Baseline in trough FEV1 at the end of the 4-week Treatment Period was defined using the pre-dose FEV1 measurement taken at the Week 4 clinic visit. Change from Baseline was calculated as the Week 4 trough FEV1 value minus the Baseline value. The Baseline FEV1 value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline trough FEV1, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.
| Liters | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 4-week Treatment Period in Children Who Could Perform the Maneuver | 0.223 ± 0.0287 | 0.166 ± 0.0292 | 0.240 ± 0.0285 | 0.193 ± 0.0288 |
The number of inhalations of rescue albuterol/salbutamol inhalation aerosol (medication used to relieve symptoms immediately) used during the day and night) was recorded by the participants in a daily diary. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Participants who were rescue free for 24-hour periods during the 4-week Treatment Period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant. Change from Baseline is calculated as the average value during the 4-week Treatment Period minus the value at Baseline. The Baseline value is defined as the value at Visit 3 (randomization). Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
| Percentage of rescue-free 24-hr periods | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 4-week Treatment Period | 14.4 ± 2.97 | 12.2 ± 2.97 | 15.8 ± 2.98 | 2.98 ± 3.01 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 4-week Treatment Period (at Week 4) minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
| L/min | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Change From Baseline in Daily Morning (AM) PEF Averaged Over the 4-week Treatment Period | 6.4 ± 2.42 | 12.0 ± 2.43 | 13.9 ± 2.44 | 13.7 ± 2.46 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline is calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.
| L/min | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Change From Baseline in Evening (PM) PEF Over the Last 7 Days of the Treatment Period (Week 4) | 5.9 ± 3.44 | 9.4 ± 3.44 | 13.7 ± 3.45 | 11.1 ± 3.48 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline is calculated as the value of the averaged daily AM PEF over the 4-week Treatment Period (at Week 4) minus the Baseline value. The Baseline value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
| L/min | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 4) | 7.4 ± 3.45 | 13.3 ± 3.47 | 17.0 ± 3.48 | 14.4 ± 3.51 |
Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the PEF measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline symptom-free value is defined as the value at Visit 3 (randomization). Change from Baseline was calculated as the averaged value during the 4-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
| Percentage of symptom-free 24-hr periods | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 4-week Treatment Period | 9.9 ± 2.65 | 10.1 ± 2.65 | 18.3 ± 2.66 | 19.7 ± 2.69 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the follow-up visit (up to 9 weeks).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/115 (0%) | 10/115 (8.7%) |
| VI 6.25 OD | — | 0/114 (0%) | 17/114 (14.9%) |
| VI 12.5 OD | — | 0/113 (0%) | 12/113 (10.6%) |
| VI 25 OD | — | 1/114 (0.9%) | 11/114 (9.6%) |
| Event | Placebo | VI 6.25 OD | VI 12.5 OD | VI 25 OD |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/115 | 0/114 | 0/113 | 1/114 |
| Event | Placebo | VI 6.25 OD | VI 12.5 OD | VI 25 OD |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/115 | 8/114 | 10/113 | 9/114 |
| HeadacheNervous system disorders | 4/115 | 6/114 | 2/113 | 2/114 |
| InfluenzaInfections and infestations | 0/115 | 4/114 | 0/113 | 0/114 |
| Age, Continuous(Years) | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD | Total |
|---|---|---|---|---|---|
| Mean | 8.0 ± 1.81 | 8.0 ± 1.95 | 7.9 ± 1.74 | 7.9 ± 1.72 | 7.9 ± 1.80 |
| Gender(Participants) | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD | Total |
|---|---|---|---|---|---|
| Female | 50 | 43 | 42 | 45 | 180 |
| Male | 65 | 71 | 71 | 69 | 276 |
| Race/Ethnicity, Customized(Participants) | Placebo | VI 6.25 µg OD | VI 12.5 µg OD | VI 25 µg OD | Total |
|---|---|---|---|---|---|
| African American/African Heritage | 5 | 5 | 5 | 3 | 18 |
| American Indian or Alaska Native | 16 | 21 | 17 | 18 | 72 |
| Asian - Japanese Heritage | 5 | 5 | 5 | 5 | 20 |
| Asian - South East Asian Heritage | 1 | 1 | 2 | 1 | 5 |
| White - Arabic/North African Heritage | 1 | 1 | 0 | 1 | 3 |
| White - White/Caucasian/European Heritage | 67 | 62 | 55 | 61 | 245 |
| Mixed Race | 20 | 19 | 29 | 25 | 93 |
Showing the first 100 of 121 sites across 14 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Apr 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vilanterol